Winslow Capital Management’s AstraZeneca AZN Stock Holding History

Winslow Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,442,416	Closed	-$200M	–	59
2023 Q1	$200M	Sell	1,442,416 -648,060	-31%	-$87.2M	1.02%	41
2022 Q4	$283M	Buy	2,090,476 +360,445	+21%	+$45.2M	1.58%	34
2022 Q3	$190M	Buy	1,730,031 +1,664,956	+2,559%	+$211M	1.11%	41
2022 Q2	$8.6M	Buy	+65,075	New	+$8.54M	0.05%	55
2021 Q2	–	Sell	-83,078	Closed	-$8.26M	–	64
2021 Q1	$8.26M	Sell	83,078 -3,090,747	-97%	-$311M	0.03%	57
2020 Q4	$317M	Buy	3,173,825 +262,557	+9%	+$27.8M	1.32%	25
2020 Q3	$319M	Sell	2,911,268 -103,325	-3%	-$11.5M	1.42%	22
2020 Q2	$319M	Sell	3,014,593 -142,905	-5%	-$14.8M	1.55%	22
2020 Q1	$282M	Buy	3,157,498 +353,748	+13%	+$33.3M	1.73%	23
2019 Q4	$280M	Sell	2,803,750 -477,151	-15%	-$44.9M	1.45%	28
2019 Q3	$292M	Buy	3,280,901 +213,229	+7%	+$18.5M	1.6%	22
2019 Q2	$253M	Sell	3,067,672 -58,401	-2%	-$4.58M	1.36%	34
2019 Q1	$253M	Buy	+3,126,073	New	+$246M	1.37%	28

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Winslow Capital Management's AZN Position: Q2 2023 in Review

Winslow Capital Management sold out of AstraZeneca (AZN) in Q2 2023, closing a stake of 1,442,416 shares — an estimated $200M sold.

Winslow Capital Management first reported a position in AZN in Q1 2019 and held it in 13 quarters. The position peaked at $319M in Q3 2020. 1,090 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

Winslow Capital Management reported no remaining AstraZeneca position as of Q2 2023 after selling out during the quarter.
Winslow Capital Management sold 1,442,416 AstraZeneca shares in Q2 2023, an estimated $200M.
Winslow Capital Management first reported a position in AstraZeneca in Q1 2019 and held it in 13 quarters.
Winslow Capital Management's AstraZeneca position peaked at $319M in Q3 2020.
1,090 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Winslow Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.